Handelsbanken Fonder AB Has $21.75 Million Stock Holdings in Kenvue Inc. $KVUE

Handelsbanken Fonder AB raised its position in Kenvue Inc. (NYSE:KVUE) by 6.5% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 1,138,036 shares of the company’s stock after acquiring an additional 69,659 shares during the period. Handelsbanken Fonder AB’s holdings in Kenvue were worth $21,748,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Physician Wealth Advisors Inc. lifted its position in shares of Kenvue by 67.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company’s stock worth $26,000 after purchasing an additional 618 shares in the last quarter. Elyxium Wealth LLC bought a new position in Kenvue in the fourth quarter valued at $26,000. MV Capital Management Inc. bought a new position in Kenvue in the fourth quarter valued at $28,000. CoreCap Advisors LLC increased its stake in Kenvue by 64.9% in the 2nd quarter. CoreCap Advisors LLC now owns 1,502 shares of the company’s stock valued at $29,000 after buying an additional 591 shares during the last quarter. Finally, Reflection Asset Management acquired a new stake in Kenvue in the 4th quarter valued at $32,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on KVUE shares. Wall Street Zen downgraded shares of Kenvue from a “buy” rating to a “hold” rating in a research note on Saturday, August 8th. UBS Group dropped their target price on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a report on Tuesday. Barclays increased their price target on Kenvue from $18.00 to $19.00 and gave the company an “equal weight” rating in a research report on Tuesday, July 21st. Zacks Research downgraded Kenvue from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, July 7th. Finally, Citigroup lowered their price target on Kenvue from $20.00 to $19.00 and set a “neutral” rating on the stock in a research report on Wednesday, April 15th. Three research analysts have rated the stock with a Buy rating and twelve have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $19.27.

Kenvue Stock Performance

Shares of KVUE opened at $18.97 on Thursday. The firm has a 50-day moving average of $18.88 and a 200-day moving average of $18.12. Kenvue Inc. has a one year low of $14.02 and a one year high of $21.95. The company has a market cap of $36.44 billion, a PE ratio of 21.80, a price-to-earnings-growth ratio of 1.36 and a beta of 0.47. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.01 and a quick ratio of 0.71.

Kenvue (NYSE:KVUE) last issued its earnings results on Thursday, August 6th. The company reported $0.31 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.32 by ($0.01). Kenvue had a net margin of 10.76% and a return on equity of 21.22%. The firm had revenue of $3.96 billion during the quarter, compared to the consensus estimate of $3.97 billion. During the same period in the previous year, the company posted $0.29 earnings per share. The firm’s revenue for the quarter was up 3.0% compared to the same quarter last year. As a group, equities analysts forecast that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, August 26th. Shareholders of record on Wednesday, August 12th will be given a dividend of $0.21 per share. This represents a $0.84 dividend on an annualized basis and a yield of 4.4%. This is a boost from Kenvue’s previous quarterly dividend of $0.21. The ex-dividend date of this dividend is Wednesday, August 12th. Kenvue’s dividend payout ratio (DPR) is presently 95.40%.

About Kenvue

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.